SCHEMBL917262

SCHEMBL917262

CNc1ccc2c(Sc3ncccc3[N+](=O)[O-])cn(Cc3cc(F)cc(F)c3)c2c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 3/20 0.35
PKM P14618 1/20 0.35
MAPT P10636 5/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 2/20 0.34
SLC29A1 Q99808 1/20 0.34
P2RX7 Q99572 2/20 0.33
NR1I2 O75469 2/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
SOS1 Q07889 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL916625 0.86 SLC6A2 (0.39) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL917261 0.86 MEN1 (0.38) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL916135 0.80 KMT2A (0.35) GAASMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL916541 0.79 MAPK1 (0.42) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL915774 0.79 KMT2A (0.42) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL916224 0.79 L3MBTL1 (0.34) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL916561 0.78 SLC6A2 (0.39) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL916280 0.78 MAPT (0.39) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL915440 0.77 MAPT (0.39) GAASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL916097 0.77 KMT2A (0.39) GAASMN1; SMN2MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009428-A1 NOVEL ANDROGENS N.V. ORGANON (NL) 2011-01-13 US disclosed
US-7812036-B2 Androgens N.V. ORGANON (NL) 2010-10-12 US disclosed
EP-1742912-B1 NOVEL ANDROGENS ORGANON NV (NL) 2010-08-25 EP disclosed
US-20070225352-A1 Novel Androgens PHARMACOPELA DRUG DISCOVERY, INC. (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225352-A1 Novel Androgens NR5A1, AR, SHBG GAA 4322/4885SMN1; SMN2 3987/4885MEN1 326/4885
US-20110009428-A1 NOVEL ANDROGENS NR5A1, AR, NR3C2 GAA 4803/4885SMN1; SMN2 3754/4885MEN1 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.